EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL

MONTVALE, N.J. – August 24, 2021 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients with severe symptoms.

The release as fetched from its publisher. eompharma.com ↗